Adjuvant therapy in esophagogastric adenocarcinoma: controversies and consensus.

ABSTRACT:

Background

Esophagogastric (EG) adenocarcinomas are aggressive malignancies. Although uncommon in the United States, gastric cancer is endemic in East Asia. In this review we focus on perioperative strategies for locally advanced EG adenocarcinomas.

Design

We summarized the results of completed phase III trials of perioperative therapy for locally advanced adenocarcinomas of the esophagus, gastroesophageal (GE) junction, or stomach. We also reviewed ongoing clinical trials.

Results

In the adjuvant setting following surgery, validated approaches include chemoradiation with a fluoropyrimidine or chemotherapy (using a fluoropyrimidine with or without platinum compound). In the neoadjuvant setting, some trials have shown a benefit for perioperative chemotherapy. Trials in

SUBMITTER: Ku GY 

PROVIDER: S-EPMC3415720 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature